So my friend, Justin Morgenstern recently put up a post on Idarucizumab, aka Praxbind. He seemed pretty fired up on the issue, so I got him on the line to talk about it. What follows is a conversation on evidence and what to do when there is not a good amount of it.
Cite this post as:
Scott Weingart. EMCrit RACC Wee – Debate re: Idarucizumab with @First10em. EMCrit Blog. Published on April 5, 2018. Accessed on April 26th 2018. Available at [https://emcrit.org/racc/debate-re-idarucizimab/ ].
Unless otherwise noted at the top of the post, the speaker(s) and related parties have no relevant financial disclosures.
You finished the 'cast,
Now get CME credit
Already an EMCrit CME Subscriber?
Click Here to Get CME Credit for the Episode
Not a subcriber yet? Why the heck not?
By subscribing, you can...
- Get CME hours
- Support the show
- Write it off on your taxes or get reimbursed by your department
If you enjoyed this post, you will almost certainly enjoy our others. Subscribe to our email list to keep informed on all of the Resuscitation and Critical Care goodness.
This Post was by the EMCrit Crew, published 3 weeks ago. We never spam; we hate spammers! Spammers probably work for the Joint Commission.